CN108774221A - A kind of GOAT inhibitor and its application in fat and diabetes - Google Patents

A kind of GOAT inhibitor and its application in fat and diabetes Download PDF

Info

Publication number
CN108774221A
CN108774221A CN201810540641.4A CN201810540641A CN108774221A CN 108774221 A CN108774221 A CN 108774221A CN 201810540641 A CN201810540641 A CN 201810540641A CN 108774221 A CN108774221 A CN 108774221A
Authority
CN
China
Prior art keywords
diabetes
benzo
acid
fat
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201810540641.4A
Other languages
Chinese (zh)
Inventor
王丽萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201810540641.4A priority Critical patent/CN108774221A/en
Publication of CN108774221A publication Critical patent/CN108774221A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A kind of application the invention discloses GOAT inhibitor and its in fat and diabetes,Wherein：R1、R2、R3It is independently selected from H, F or CH3.Tested by pharmacological activity when confirming 10 μM of the compounds of this invention has preferable inhibitory activity to GOAT, GOAT inhibitor can be used as to carry out more extensive pharmacological effect experiment in the disease animal models such as fat and diabetes, to obtain the fat and new medicine of diabetes.

Description

A kind of GOAT inhibitor and its application in fat and diabetes
Technical field
The invention belongs to chemical medicines, are related to a kind of GOAT inhibitor and its application in fat and diabetes.
Background technology
Today's society, obesity patient's quantity increase severely in the world, and show the apparent trend that becomes younger, overweight With fat so that ascendant trend is presented in the incidence of other Chronic Non-Communicable Diseases of China, it is strong that obesity has become influence resident One of public safety problem of health.Obesity needs to obtain long-term treatment as a kind of chronic metabolic class disease.It is moving With lifestyle change, diet control it is invalid in the case of, drug therapy is particularly important.Currently, anti-obesity drug Developing history is relatively short, requires higher to Drug safety and validity, in recent years, anti-obesity medicament research and development causes Researchers pay close attention to, but clinically bariatrician is very few.Meanwhile some marketed drugs because drug safety with Side-effect problem and be forced to remove city, be currently available that anti-obesity drug is very few.
Diabetes are common disease in crowd, high morbidity, are with high caused by hypoinsulinism or insulin resistance The incretion metabolism disease that blood glucose is characterized has become the third-largest harm human health for being only second to angiocardiopathy and cancer Disease.Diabetes are the impaired diseases of Patients' rights blood glucose ability, and patient has lost to some extent makees insulin With the ability for making appropriate reaction.It is largely type II diabetes (i.e. Non-Insulin Dependent Diabetes Mellitus) in diabetes, accounts for about 80%-90%, the study found that the insulin resistance of peripheral tissues' (including skeletal muscle, liver and adipose tissue etc.) is in II type sugar It urinates in sick generation, development and plays particularly important effect.
Ghrelin O- acyltransferases (ghrelin O-acyltransferase, GOAT) belong to film combination O- acyltransferases (MBOAT) enzyme family.Aliphatic acid by being transferred to the Ser3 residues of acyl group ghrelin by it Acyl group-ghrelin (also referred to as 1-28 UAG or UAG) will be gone to be converted to biologically active form acyl group-life Long element release peptide (AG).Acyl group-ghrelin in the mankind and rodent has been displayed to increase food intake and increase fertilizer It is fat.Also it has been displayed and is transfused the insulin secretion that AG inhibits glucose induction in people.Disappearing for ghrelin gene has been displayed The glucose intolerance in ob/ob mouse except enhancing insulin releasing to prevent or improve feeding high fat diet.
However, fat and diabetes prevalences and obesity are with the different validity of the Current therapeutic of diabetes and to treatment Reaction make patient it is necessary to obtain more therapeutic choices.GOAT inhibitor as diet and/or movement, be designed to subtract The auxiliary of few weight gain or the fat other healing potions or program for the treatment of, it can also be used to reduce weight gain or weight is anti- Bullet.GOAT inhibitor can combine individually or with the other therapies of diabetes B and be used to treat diabetes B.
Invention content
The invention discloses a kind of benzo [b] thiophenes, general structure is formula I
Wherein：R1、R2、R3It is independently selected from H, F or CH3.The present invention Further relate to the pharmaceutically acceptable salt or solvate of the Formula I.
Further, benzo [b] thiophenes formula described in some preferred schemes I are
The synthetic route that another object of the present invention discloses benzo [b] the thiophenes formula I is：
Specifically synthetic method is：Its synthesis step is as follows：
1) hydroxyl position (- OH) and isoxazole -5- carbonyls chlorine (compound 2) contract in compound 1 in a suitable solvent Reaction is closed, compound 3 is generated；
2) halogenation generation compound 4 occurs for compound 3 and NBS；
3) under cryogenic conditions, the sulphur in benzothiophene ring in compound 4 is oxidized to sulfinyl and generates compound 5；
4) compound 5 is undergone coupling reaction to produce with corresponding alcohol under the action of solvent DMF and inorganic base corresponding Sulfinyl derivative；
5) sulfinyl in previous step product is in H2Hydrogenization and Pd/C catalytic action under be reduced to sulphur, it is raw At final product benzo [b] thiophene derivants.
Wherein, the solvent in the step 1) can be dichloromethane, 1,2- dichloroethanes, second eyeball, N, N- dimethyl methyls Amide (DMF), tetrahydrofuran, ethyl acetate, toluene, dimethylbenzene or other suitable solvents, preferably tetrahydrofuran.
Wherein, the temperature range of sub-cooled is -15~-10 DEG C, preferably -10 DEG C in the step 3).
Wherein, the inorganic base in the step 4) can be potassium ethoxide, sodium ethoxide, potassium tert-butoxide, sodium tert-butoxide etc., preferably Potassium tert-butoxide.
Another object of the present invention provides the benzo [b] thiophenes and turns as ghrelin O- acyl groups Move the application of enzyme (GOAT) inhibitor.
Another object of the present invention provides the benzo [b] thiophenes in prevention or obesity treating medicine Application.
Another object of the present invention provides the benzo [b] thiophenes in preventing or treating diabetes medicament Application.Further, the diabetes are type II diabetes and/or obese diabetic.
Related disease further includes with ghrelin (ghrelin)：Obesity, interior fat syndrome, non-alcohol Property fatty liver, nonalcoholic steatohepatitis, metabolic syndrome, diabetes are (for example, type-1 diabetes mellitus, type-2 diabetes mellitus, the gestational period Diabetes, obese diabetes), post prandial hyperglycemia, hyperlipidemia (for example, hypertriglyceridemia, hypercholesterolemia, High LDL- cholesteremias, low HDL-cholesteremia, postprandial hyperlipemia), the complication of diabetes (for example, neuropathy, nephrosis, Retinopathy, cardiomyopathy, huge angiosis, sclerotin reduction, hyperosmolar coma, gangrene, xerostomia, hypacusia, cerebrovascular condition, Peripheral blood circulatory disorders, infection are (for example, respiratory tract infection, urinary tract infections, gastrointestinal infection, epidermis soft tissue infection, lower limb sense Dye), diabetic gangrene), digestive disease (for example, irritable bowel syndrome, acute or chronic diarrhea, functional gastrointestinal disease, Ulcerative colitis, acute corrosive esophagitis, acute corrosive gastritis, Crohn disease, acute pancreatitis, chronic pancreatitis), kidney Dirty disease is (for example, chronic nephritis, nephrosis, glomerulonephritis, glomerulosclerosis, kidney failure, End-stage renal disease Disease, hypertensive nephrosclerosis, pyelonephritis, water nephrosis), circulation system disease is (for example, ischemic heart disease (myocardial infarction, the heart Angina), cardiomegaly, cardiomyopathy, hypertension, artery sclerosis, arrhythmia cordis, heart failure, coronary heart disease, endocarditis, artery Tumor, mitral valve prolapse, venous thromboembolism, valvular inadequacy), autoimmune disease is (for example, rheumatoid arthritis, more Hair property hardening, psoriasis, systemic loupus erythematosus, Sjogren's syndromes) etc. and growth disorder (for example, acra is fertile Big disease, giantism), Chronic Obstructive Pulmonary Disease, pneumonia, spill smart dependence, excitant dependence, narcotic dependence, tobacco Dependence, gambling dependence, eating disorder are (for example, bulimia, neuropath's bulimia, mad food illness, Prader- Willi syndromes), prostate cancer, breast cancer, hypophysis tumor, ovarian neoplasm, carcinoma of uterine body, neck cancer, etc..
Pharmaceutically acceptable salt of the present invention refers to the organic salt and inorganic salts of the compounds of this invention.Pharmaceutically may be used The acid-addition salts of receiving can be formed with inorganic acid and organic acid, including but not limited to, acetate, aspartate, benzene first Hydrochlorate, benzene sulfonate, bromide/hydrobromate, bicarbonate/carbonate, disulfate/sulfate, camsilate (camphorsulfornate), chloride/hydrochloride, chloro theophylline salt (chlortheophyllonate), citrate, second two Sulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydriodate/iodide, hydroxyl second Base sulfonate, lactate, Lactobionate, lauryl sulfate, malate, maleate, malonate, mandelate, Mesylate, Methylsulfate, naphthoate, naphthalene sulfonate, nicotinate, nitrate, octadecane hydrochlorate, oleate, oxalates, Palmitate, embonate, phosphate/phosphor acid hydrogen salt/dihydric phosphate, Polygalacturonate, propionate, stearic acid Salt, succinate, sulfosalicylate, tartrate, toluene fulfonate and trifluoroacetate.Can the nothing of salt be obtained by its derivative Machine acid includes such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid.The organic acid that salt can be obtained by its derivative includes such as second Acid, propionic acid, glycolic, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, Methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid etc..
Solvate of the present invention refers to that one or more solvent molecules are formed by with the compound of the present invention and form Close object.The solvent for forming solvate includes, but is not limited to, water, isopropanol, ethyl alcohol, methanol, dimethyl sulfoxide, ethyl acetate, Acetic acid and ethylaminoethanol.
Specific embodiment
Embodiment 1：The synthesis of 2- (furans -2- oxygroups) benzo [b] thiophene -6- base isoxazole -5- methyl formates
The synthesis of 1-1, benzo [b] thiophene -6- base isoxazole -5- carboxylic acid, ethyl esters：
In a nitrogen atmosphere, by benzo [b] thiophene -6- alcohol (compound 1) (5.86g, 39.01mmol), 4- dimethylaminos After pyridine DMAP (473mg, 3.87mmol) is dissolved in together in THF (100mL), add triethylamine (4.15g, 41.03mmol) with isoxazole -5- acyl chlorides (compound 2) (40.99mmol), it is heated to reflux mixture and holds 7 hours, it then will be anti- 50 DEG C should be cooled to.Add the mixture of water (20mL) and acetic acid (3.67mL), the solution being layered.Detach organic layer simultaneously Give up water layer, you can the THF solution of benzo [b] thiophene -6- base isoxazole -5- carboxylic acid, ethyl esters (compound 3) is obtained, by the solution It is directly used in the synthesis of next step.1H-NMR(400MHz,CDCl3)δ:6.04(d,1H),7.32-7.42(m,3H),7.58 (d,1H),7.75(dd,1H),8.42(d,1H).13C-NMR(125MHz,CDCl3)δ:106.85,113.16,118.59, 122.13,122.15,124.54,135.42,140.36,148.29,153.55,157.07,160.36.LC-MS(ESI,pos, ion)m/z:246[M+H].
The synthesis of 1-2,2- bromobenzene simultaneously [b] thiophene -6- bases isoxazole -5- carboxylic acid, ethyl esters：
NBS (7.30g, 40.99mmol) is added in the solution that synthesis step 1-1 is obtained at room temperature, is stirred Object 30 minutes.Then acquired solution is distilled to 50mL, methanol (25mL) is added and solution is cooled to 50 DEG C, then to this Crystal seed 2- bromobenzenes simultaneously [b] thiophene -6- base isoxazole -5- carboxylic acid, ethyl esters (331mg, 0.8mmol) are added in cooling solution, then Stir mixture 20 minutes.It is slowly added to water (45mL) so that mixture is cooled to room temperature and maintains 1 hour.Pass through vacuum mistake Product is collected in filter, and aqueous solution (30mL, the water of THF is used in combination：THF=2:1) it is washed, and dry in vacuum drying oven, is obtained Simultaneously [b] thiophene -6- base isoxazole -5- carboxylic acid, ethyl esters (compound 4), yield are 82% to the 2- bromobenzenes of 10.36g.1H-NMR (400MHz,CDCl3)δ:6.04(d,1H),7.32-7.38(m,2H),7.58(d,1H),7.75(dd,1H),8.42(d,1H) .13C-NMR(125MHz,CDCl3)δ:106.85,110.13,112.5,117.65,122.18,122.42,134.51, 139.23,148.91,153.55,157.07,160.36.LC-MS(ESI,pos,ion)m/z:325[M+H].
The synthesis of bromo- 1- oxos benzo [b] thiophene -6- bases isoxazole -5- carboxylic acid, ethyl esters of 1-3,2-：
At -10 DEG C, the compound 4 (10.36g, 31.98mmol) that synthesis step 1-2 is obtained is added to sulfolane In the solution of (110mL) and sulfuric acid (55mL), 30% hydrogen peroxide (20.25mL) is then added dropwise, is dripped within 3 hours It adds into, and keeps temperature always close to -10 DEG C.After being added dropwise to complete, stirring mixture 1 hour takes sample and measures and reacted At.After the completion of reaction once, any possible remaining oxidant is quenched with 5% aqueous solution of sodium bisulfite (85mL).Then Acetic acid (27.5mL) is added into this mixture and adjusts temperature to 20~25 DEG C.The bromo- 1- oxos of 2- are added into this mixture Then benzo [b] thiophene -6- base isoxazole -5- carboxylic acid, ethyl esters (compound 5) (6.85mmol) are stirred 2 hours with growing crystal To promote crystal growth.After 2 hours, slowly add water (150mL) to complete to crystallize within 3 hours.Then slurries at least 2 are stirred It is filtered after hour.Then water (85mL), ammonium hydroxide (14%, 85mL) and water (85mL) is used to wash filter cake successively.Gained is wet Filter cake is dissolved at 65 DEG C in the two phase liquid of ethyl acetate (140mL) and water (127.5mL), and then the product of stirring and dissolving is extremely It is 30 minutes few, then remove following water layer.Then compound 5 (6.85mmol) is added to 60~65 DEG C in cooling solution temperature To grow crystal.Slurries are cooled to 0-5 DEG C by growing the grain 30~60 minutes in 2-3 hours.Products obtained therefrom is filtered, is used in combination cold (0~5 DEG C) ethyl acetate solution is washed, then the dry products at 50~60 DEG C of vacuum, you can obtains the 2- of 7.59g Bromo- 1- oxos benzo [b] thiophene -6- base isoxazole -5- carboxylic acid, ethyl esters (compound 5), yield is 70%.1H-NMR(400MHz, CDCl3)δ:6.04(d,1H),7.44-7.51(m,3H),7.62(s,1H),8.42(d,1H).13C-NMR(125MHz,CDCl3) δ:106.85,117.34,127.18,135.09,136.69,141.24,151.08,153.55,157.07,160.36.LC-MS (ESI,pos,ion)m/z:340[M+H].
The synthesis of 1-4,2- furans -2- Oxy-1s-oxo benzo [b] thiophene -6- bases-isoxazole -5- methyl formates：
Furans -2- alcohol (25.08mmol) is added into container, potassium tert-butoxide then is added into this container The THF solution of (25.03mmol) is then rinsed using the DMF less than 100mL, and agitating solution about 15 minutes is to ensure furan It mutters the complete deprotonation of -2- alcohol.The compound 5 (7.59g, 22.39mmol) that synthesis step 1-3 is obtained is added in supplemental tank, (furans -2- alcohol for including deprotonation) is transferred the material into reaction vessel with the DMF no more than 100-500mL, then will It is transferred in reaction vessel.The solution of eluant container is also transferred in reactor using DMF.Reactor is heated to 50 DEG C, and aging 4 hours at 50 DEG C, or until reaction assay terminates, be displayed without more compounds 5 and be converted into 2- furans It mutters -2- Oxy-1s-oxo benzo [b] thiophene -6- bases-isoxazole -5- methyl formates, solution is directly used in next step.1H-NMR (400MHz,CDCl3)δ:5.80(dd,1H),6.02(d,1H),6.32(t,1H),6.79(s,1H),7.41-7.48(m,4H), 8.39(d,1H).13C-NMR(125MHz,CDCl3)δ:88.64,106.85,109.16,119.73,124.3,130.29, 132.04,133.65,139.33,150.6,151.74,153.55,157.07,160.36.LC-MS(ESI,pos,ion)m/z: 344[M+H].
The synthesis of 1-5,2- (furans -2- oxygroups) benzo [b] thiophene -6- bases-isoxazole -5- methyl formates：
In the organic layer obtained to synthesis step 1-4 be added 75% phosphoric acid (about 140mL), until pH be less than 2.0, then The solution of acidification is transferred in hydrogenator, and 10%Pd/C catalyst (4.3g) is added.With the deionized water of 0.5L/kg (225ml) rinses catalyst and is directly entered dehydrogenator.It is hydrogenated under the Hydrogen Vapor Pressure of 65psi at 110 DEG C.Then from hydrogenator It is middle to take out the suspension containing 2- (furans -2- oxygroups) benzo [b] thiophene -6- bases-isoxazole -5- methyl formates, filter aid is used in combination Filtration catalytic agent, vacuum shift solvent, and flash column chromatography separation obtains 4.98g yellow powders, two step gross production rates 68%.1H- NMR(400MHz,CDCl3)δ:5.80(dd,1H),6.04(d,1H),6.35(t,1H),6.53(d,1H),7.32(dd,1H), 7.44(dd,1H),7.58(d,1H),7.75(dd,1H),8.42(d,1H).13C-NMR(125MHz,CDCl3)δ:88.64, 106.85,109.03,109.16,114.05,116.48,123.44,129.24,139.33,147.48,147.97,151.74, 153.55,157.07,160.14,160.36.LC-MS(ESI,pos,ion)m/z:328[M+H]。
Embodiment 2：The synthesis of 2- (the fluoro- isoquinolin -8- oxygroups of 6-) benzo [b] thiophene -6- base isoxazole -5- methyl formates
The conjunction of 2-1,2- (5- fluoro- furans-2) Oxy-1-oxo benzo [b] thiophene-6- bases-isoxazole-5- methyl formates At：
Fluoro- furans -2- the alcohol (25.08mmol) of 5- are added into container, potassium tert-butoxide then is added into this container The THF solution of (25.03mmol) is then rinsed using the DMF less than 100mL, and agitating solution about 15 minutes is to ensure 5- The fluoro- complete deprotonation of furans -2- alcohol.Compound 5 (7.59g, 22.39mmol) is added in supplemental tank, with no more than 100- The DMF of 500mL transfers the material into reaction vessel (the fluoro- furans -2- alcohol of 5- for including deprotonation), is then transferred to In reaction vessel.The solution of eluant container is also transferred in reactor using DMF.Reactor is heated to 50 DEG C, and 50 Aging 4 hours at DEG C, or until reaction assay terminates, be displayed without more compounds 5 and be converted into 2- (5- fluoro- furans -2) Oxy-1-oxo benzo [b] thiophene-6- bases-isoxazole-5- methyl formates, solution are directly used in next step.LC-MS(ESI, pos,ion)m/z:362[M+H].
The synthesis of 2-2,2- (the fluoro- furans -2- oxygroups of 5-) benzo [b] thiophene -6- bases-isoxazole -5- methyl formates：
In the organic layer obtained to synthesis step 2-1 be added 75% phosphoric acid (about 140mL), until pH be less than 2.0, then The solution of acidification is transferred in hydrogenator, and 10%Pd/C catalyst (4.3g) is added.With the deionized water of 0.5L/kg (225ml) rinses catalyst and is directly entered dehydrogenator.It is hydrogenated under the Hydrogen Vapor Pressure of 65psi at 110 DEG C.Then from hydrogenator The middle suspension for taking out 2- (the fluoro- furans -2- oxygroups of 5-) benzo [b] thiophene -6- bases-isoxazole -5- methyl formates, is used in combination drainage Agent filtration catalytic agent, vacuum shift solvent, and flash column chromatography separation obtains 5.56g yellow powders, two step gross production rates 72%.LC- MS(ESI,pos,ion)m/z:346[M+H]。
Embodiment 3：The conjunction of 2- (5- methyl-ribofuranosyl -2- oxygroups) benzo [b] thiophene -6- bases-isoxazole -5- methyl formates At
The conjunction of 3-1,2- (5- methyl-ribofuranosyls-2) Oxy-1-oxo benzo [b] thiophene-6- base isoxazole-5- methyl formates At：
5- methylfuran -2- alcohol (25.08mmol) is added into container, potassium tert-butoxide then is added into this container The THF solution of (25.03mmol) is then rinsed using the DMF less than 100mL, and agitating solution about 15 minutes is to ensure 5- The complete deprotonation of methyl-ribofuranosyl -2- alcohol.By compound 5 (7.59g, 22.39mmol) be added supplemental tank in, with no more than The DMF of 100-500mL transfers the material into reaction vessel (the 5- methyl-ribofuranosyl -2- alcohol for including deprotonation), then by it It is transferred in reaction vessel.The solution of eluant container is also transferred in reactor using DMF.Reactor is heated to 50 DEG C, And aging 4 hours at 50 DEG C, or until reaction assay terminate, be displayed without more compounds 5 and be converted into 2- (5- first Base-furans-2) Oxy-1-oxo benzo [b] thiophene-6- base isoxazole-5- methyl formates, solution be directly used in next step.LC- MS(ESI,pos,ion)m/z:358[M+H].
The synthesis of 3-2,2- (5- methyl-ribofuranosyl -2- oxygroups) benzo [b] thiophene -6- bases-isoxazole -5- methyl formates：
In the organic layer obtained to synthesis step 3-1 be added 75% phosphoric acid (about 140mL), until pH be less than 2.0, then The solution of acidification is transferred in hydrogenator, and 10%Pd/C catalyst (4.3g) is added.With the deionized water of 0.5L/kg (225ml) rinses catalyst and is directly entered dehydrogenator.It is hydrogenated under the Hydrogen Vapor Pressure of 65psi at 110 DEG C.Then from hydrogenator It is middle to take out the suspension containing 2- (5- methyl-ribofuranosyl -2- oxygroups) benzo [b] thiophene -6- bases-isoxazole -5- methyl formates, it is used in combination Filter aid catalyst, vacuum shift solvent, and flash column chromatography separation obtains 4.96g yellow powders, two step gross production rates 65%.LC-MS(ESI,pos,ion)m/z:342[M+H].
Test example：External inhibitory activity of the compounds of this invention to GOAT
One, the structure of GOAT expression plasmids
With PCR amplification people GOAT (registration number EU518495) cDNA, including following reaction：(1) 98 DEG C, 1 minute, (2) 35 98 DEG C of secondary repetition, 10 seconds 65 DEG C, 15 seconds 72 DEG C, 80 seconds, and (3) 72 DEG C, 5 minutes, people's stomach cDNA used as template Library (Takara Bio) and Pyrobest archaeal dna polymerases (TakaraBio).By amplified fragments restriction enzyme treatment, make With Ligation High (TOYOBO), the Stu I/Not I sites of pFastBac1 (Invitrogen) are inserted it into, and turn It contaminates in ECOS JM109 (Nippon Gene), builds pFB/hGOAT.
Two, virus amplification and people's GOAT expression
In order to prepare baculoviral (baculovirus) by pFB/hGOAT, BacToBac baculovirus expression systems are used (Invitrogen).Using SYBR Green (Takara Bio), virus titer is measured by real-time PCR.Make Sf9 cell senses Obtained baculoviral, multiple infections (MOI)=0.2 are caught, and are cultivated 70 hours.Sf9 cells are recycled, suspension is suspended in In buffer solution (TBS (0.3M NaCl), 1mM DTT, 1mM EDTA, Complete (Roche) (1tablet/50mL)), and make With polytron homogenizers, on ice, at 20000rpm by the cell fragmentation 30 seconds.At 4 DEG C, smudge cells solution is existed Centrifuged 10 minutes under 1000rpm, by supernatant at 4 DEG C, at 40000rpm further ultracentrifugation 30 minutes, and recycle precipitation. The precipitation of acquisition is suspended in the buffer suspension liquid being used above, obtains people's GOAT expression microsome fractions.Use BCA albumen Testing reagent (PIERCE) measures protein level.
Three, enzymatic activity is measured using HTRF methods
It will be diluted and be reached with experiment buffer solution (containing 50mM Tris-HCl (pH7.5), 0.5%TWEEN20 and Complete) 20 points are cultivated at room temperature to the compound solution (2 μ L) of 15%DMSO and 90 μ g/mL people GOAT expression microsome fractions (2 μ L) Clock then will contain 30 μM of caprylyl CoA (CHEM-IMPLEX) and 3 μM of ghrelin (Ghrelin)-biotins (biotin)(Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu- Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-epsilon aminocaproic acids-biotin (Greiner Coutom synthesis)) substrate mixed solution be added in the white small size plate (Greiner) in 384 (holes).20 points of reaction After clock, citrate buffer (pH3) (0.1M citric acids (39.8mL) and the 0.2M Na of 2 μ L is added2HPO4(10.2mL's) Mixed solution), the Eu (K)-of 25nM resistant activities ghrelin (ghrelin) antibody (being generated in mouse) of 2 μ L, 5 μ L The streptavidin-of anti-mouse IgG Pab (CisBio) (diluting 100 times with HTRF detection buffer solutions (Cis Bio)) and 5 μ L Xlent (Cis Bio) (dilutes 66.6 times) with HTRF detection buffer solutions (CisBio).When cultivating 1 hour or longer at room temperature Between after, utilize Envision (PerkinElmer) measure 620nm and 665nm under fluorescent value.Calculating data, [(665nm believes Number/620nm signals) × 104], it is indicated by data for the inhibitory activity of people GOAT, wherein 0% reference material is free from chemical combination Object, 100% reference material are free from enzyme.Four, to the inhibiting rate of GOAT when 10 μM of compound
Illustrate that there is preferable inhibitory activity to GOAT when 10 μM of the compounds of this invention, can exist as GOAT inhibitor More extensive pharmacological effect experiment is carried out in the disease animal models such as fat and diabetes, it is new to obtain fat and diabetes Medicine.

Claims (7)

1. a kind of benzo [b] thiophenes, general structure is formula I,
Wherein：R1、R2、R3It is independently selected from H, F or CH3。
2. the pharmaceutically acceptable salt or solvate of benzo [b] thiophenes as described in claim 1.
3. benzo [b] thiophenes as described in claim 1, characterized in that be selected from following compound：
4. benzo [b] thiophenes as claimed in claim 1 or 2 inhibit as ghrelin O- acyltransferases The application of agent.
5. application of benzo [b] thiophenes as claimed in claim 1 or 2 in prevention or obesity treating medicine.
6. application of benzo [b] thiophenes as claimed in claim 1 or 2 in preventing or treating diabetes medicament.
7. application as claimed in claim 6, characterized in that the diabetes are type II diabetes and/or obese diabetic.
CN201810540641.4A 2018-05-30 2018-05-30 A kind of GOAT inhibitor and its application in fat and diabetes Withdrawn CN108774221A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810540641.4A CN108774221A (en) 2018-05-30 2018-05-30 A kind of GOAT inhibitor and its application in fat and diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810540641.4A CN108774221A (en) 2018-05-30 2018-05-30 A kind of GOAT inhibitor and its application in fat and diabetes

Publications (1)

Publication Number Publication Date
CN108774221A true CN108774221A (en) 2018-11-09

Family

ID=64027969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810540641.4A Withdrawn CN108774221A (en) 2018-05-30 2018-05-30 A kind of GOAT inhibitor and its application in fat and diabetes

Country Status (1)

Country Link
CN (1) CN108774221A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254525A (en) * 2012-02-24 2014-12-31 武田药品工业株式会社 Aromatic ring compound
CN105636948A (en) * 2013-11-14 2016-06-01 伊莱利利公司 Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254525A (en) * 2012-02-24 2014-12-31 武田药品工业株式会社 Aromatic ring compound
CN105636948A (en) * 2013-11-14 2016-06-01 伊莱利利公司 Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor

Similar Documents

Publication Publication Date Title
CN102770415B (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
CN105121432B (en) Heterocycleamide as kinase inhibitor
CN103347510B (en) Lpa receptor antagonist and the purposes in treatment fibrosis thereof
CN101106990B (en) Compounds and compositions as protein kinase inhibitors
CN101511813B (en) Heterocyclic FXR binding compounds
RU2628077C2 (en) New derivative of 3-(4-(benzyloxy)phenyl)hex-4-ine acid, method for its production and pharmaceutical composition for metabolic disease prevention and treatment including it as effective ingredient
US7605164B2 (en) Compositions and methods for treating heart failure
US20100048561A1 (en) Quinazolines for pdk1 inhibition
TW200811188A (en) Pharmaceutical compounds
JP2010514693A (en) Quinazoline for PDK1 inhibition
CN107252424A (en) New FXR（NR1H4）With reference to and activity modulating compounds
TW200918527A (en) Piperazine derivative having affinity for the histamine H3 receptor
CN101817767A (en) Substituted sulphonamide compound and preparation method, medicine composition and application thereof
CN111658653B (en) Use of phosphodiesterase inhibitors
TW200808709A (en) Novel compounds
CN106831824A (en) Pyrrolopyridines and its application containing naphthyridones structure
CN113402499B (en) Sulfimide substituted indazole IRAK4 kinase inhibitor, preparation method and application
CN107286156A (en) New URAT1 inhibitor and its in application pharmaceutically
CN106674136A (en) Anti-tumor pyrimidine compounds and preparation method thereof
CN108774221A (en) A kind of GOAT inhibitor and its application in fat and diabetes
CN108516972A (en) A kind of GOAT inhibitor and its application in fat and diabetes
CN108558852A (en) A kind of GOAT inhibitor and its application in fat and diabetes
CN108516971A (en) A kind of benzo [b] thiophenes and its application in fat and diabetes
TW200908967A (en) Pyrazolo-pyridinone compounds and methods of use thereof
CN108558849A (en) A kind of benzo [b] thiophenes and its application in fat and diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20181109

WW01 Invention patent application withdrawn after publication